Revenue distribution by sectors:

• Biopharmaceuticals: 70%
• Diagnostics: 20%
• Research and Development: 10%

TOP 3 markets and their shares:

• China: 45%
• USA: 30%
• Europe: 15%

Keymed Biosciences Inc. generates the majority of its revenue from the biopharmaceutical sector, which is attributed to its strong product lines and innovations in this area. The Chinese market is the largest single market for the company, followed by the USA and Europe, highlighting Keymed's international reach and strategic market positioning.

Production Sites: Chengdu, China

Keymed Biosciences Inc. mainly produces its products in Chengdu, China. The company has modern production facilities there that specialize in the manufacturing of biopharmaceutical products. This strategic location choice enables Keymed to benefit from well-developed infrastructures and proximity to important scientific and technological resources in the region.

Focus on R&D Investments: 30% of revenue (2025)

Expansion of Product Pipeline: 5 new products in clinical trials (2025)

International Expansion: Market entry into 3 new countries (2025)

Keymed Biosciences Inc. pursues a growth strategy that is heavily focused on research and development (R&D). The company invests approximately 30% of its revenue in R&D to expand its product pipeline and develop innovative therapies.

Another key focus is on expanding the product pipeline. Keymed currently has five new products in various stages of clinical trials, increasing the potential for future market launches.

Furthermore, the company is focusing on international expansion by entering new markets. By 2025, Keymed plans to expand into three new countries to strengthen its global presence and tap into new revenue sources.

Main raw materials: Biopharmaceutical active ingredients, laboratory chemicals

Countries of origin: USA, Germany, China

Keymed Biosciences Inc. mainly imports biopharmaceutical active ingredients and specialized laboratory chemicals needed for the research and development of new drugs. These materials primarily come from the USA and Germany, known for their advanced biotechnological industries. Additionally, the company also sources some raw materials from China to benefit from more cost-effective production capabilities.

This strategic sourcing enables Keymed to develop high-quality products while optimizing costs. The selection of supplier countries reflects the need to rely on reliable and innovative sources to succeed in the competitive biotechnology industry.

Market Share: 8% (estimated, 2026)

R&D Expenses: 25% of revenue (2025)

Keymed Biosciences Inc. has established itself as a significant player in the biotechnology industry in recent years. The company's competitive advantage is primarily based on its strong research and development (R&D), to which it invests a substantial portion of its revenue. These investments enable Keymed to develop innovative products and compete in a dynamic market environment.

Another advantage is the strategic partnership with leading pharmaceutical companies, which facilitates market access and increases distribution reach. These collaborations strengthen Keymed's position in the competition and contribute to the company's stability.

Despite these advantages, Keymed operates in a fiercely competitive market where continuous innovation and adaptation are necessary to remain successful in the long term.

Institutional Investor Share: approximately 45% (2026, estimated)

Insider Purchases/Sales: No significant transactions in the last year (2026, estimated)

The institutional investor share in Keymed Biosciences Inc. is estimated to be around 45%. This share reflects the confidence of institutional investors in the company's long-term strategy and growth potential.

In 2026, there were no significant insider transactions, indicating that the management and other insiders are currently not making any significant changes to their stake in the company. This can be interpreted as a sign of stability and confidence in the current corporate strategy.

Market share of Keymed Biosciences Inc.: Estimated 3-5% (2026)

Top competitors and their market shares:

1. BeiGene Ltd.: 15%
2. Innovent Biologics Inc.: 12%
3. Zai Lab Ltd.: 10%
4. Junshi Biosciences: 8%
5. Hutchmed China: 7%
6. Keymed Biosciences Inc.: 3-5%
7. CStone Pharmaceuticals: 3%
8. CanSino Biologics: 2%
9. Harbour BioMed: 2%
10. I-Mab Biopharma: 2%

The market share of Keymed Biosciences Inc. is in the mid-single digits, indicating a solid but not market-leading position. The company competes in a dynamic and highly competitive market environment, especially in the field of biopharmaceuticals.

Economic moat of Keymed Biosciences Inc.:

Keymed Biosciences has made a name for itself through specialized research and development in specific therapeutic areas. The company's economic moat is based on its innovation capabilities and its ability to develop new and effective therapies. This provides some protection against competitors who may not have the same R&D expertise.

However, compared to leading companies like BeiGene or Innovent Biologics, which have more extensive product pipelines and larger financial resources, Keymed's economic moat is less pronounced. These larger competitors often have the advantage of being able to react more quickly to market changes and possess established distribution networks that give them a competitive edge.

Overall, Keymed Biosciences has a moderate economic moat, which is somewhat mitigated by strong competition and their competitors' more comprehensive resources. To strengthen the economic moat, Keymed could invest in strategic partnerships or further diversify its product pipeline.

Revenue Growth: 18% (2025) Research and Development Expenses: 35% of revenue (2025) Market Share in the Biotechnology Industry: 4% (2025)

Keymed Biosciences Inc. shows a strong revenue growth of 18% in 2025, indicating successful product developments and an effective market launch strategy. The company invests significantly in research and development, accounting for 35% of revenue. This suggests that Keymed is striving to expand its product pipeline and bring innovative solutions to the market.

With a market share of 4% in the biotechnology industry, Keymed positions itself as a relevant player. Continuous investments in research and development could place the company in an advantageous position for future growth, especially if new products are successfully launched.

Overall, Keymed Biosciences Inc. appears to be an interesting investment opportunity due to its strong growth figures and strategic focus on innovation, provided that market conditions remain stable and product developments are successful.

Dividend payment: No dividend (2026)

Keymed Biosciences Inc. has not paid any dividends so far. The company focuses on research and development in the field of biosciences, which typically involves high investments and a focus on growth.

In the biotechnology industry, it is not uncommon for companies in the growth phase to not pay dividends as they reinvest their profits to expand their product pipelines and strengthen their market position. Therefore, the reliability of a future dividend payment is currently difficult to estimate.